PMID- 24383005
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140102
LR  - 20211021
IS  - 2090-3170 (Print)
IS  - 2090-3189 (Electronic)
IS  - 2090-3189 (Linking)
VI  - 2013
DP  - 2013
TI  - Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ 
      Hybridization for Low and High Throughput HER2 Genetic Testing.
PG  - 368731
LID - 10.1155/2013/368731 [doi]
LID - 368731
AB  - The purpose was to evaluate and compare 5 different HER2 genetic assays with 
      different characteristics that could affect the performance to analyze the human 
      epidermal growth factor 2 (HER2) gene copy number under low and high throughput 
      conditions. The study included 108 tissue samples from breast cancer patients 
      with HER2 immunohistochemistry (IHC) results scored as 0/1+, 2+, and 3+. HER2 
      genetic status was analysed using chromogenic in situ hybridization (CISH) and 
      fluorescence in situ hybridization (FISH). Scoring results were documented 
      through digital image analysis. The cancer region of interest was identified from 
      a serial H&E stained slide following tissue cores were transferred to a tissue 
      microarrays (TMA). When using TMA in a routine flow, all patients will be tested 
      for HER2 status with IHC followed by CISH or FISH, thereby providing individual 
      HER2 results. In conclusion, our results show that the differences between the 
      HER2 genetic assays do not have an effect on the analytic performance and the 
      CISH technology is superior to high throughput HER2 genetic testing due to 
      scanning speed, while the IQ-FISH may still be a choice for fast low throughput 
      HER2 genetic testing.
FAU - Poulsen, Tim S
AU  - Poulsen TS
AD  - Molecular Unit, Department of Pathology, Herlev Hospital, University of 
      Copenhagen, Herlev Ringvej 75, 2730 Herlev, Denmark.
FAU - Espersen, Maiken L M
AU  - Espersen ML
AD  - Molecular Unit, Department of Pathology, Herlev Hospital, University of 
      Copenhagen, Herlev Ringvej 75, 2730 Herlev, Denmark.
FAU - Kofoed, Vibeke
AU  - Kofoed V
AD  - Molecular Unit, Department of Pathology, Herlev Hospital, University of 
      Copenhagen, Herlev Ringvej 75, 2730 Herlev, Denmark.
FAU - Dabetic, Tanja
AU  - Dabetic T
AD  - Molecular Unit, Department of Pathology, Herlev Hospital, University of 
      Copenhagen, Herlev Ringvej 75, 2730 Herlev, Denmark.
FAU - Hogdall, Estrid
AU  - Hogdall E
AD  - Molecular Unit, Department of Pathology, Herlev Hospital, University of 
      Copenhagen, Herlev Ringvej 75, 2730 Herlev, Denmark.
FAU - Balslev, Eva
AU  - Balslev E
AD  - Molecular Unit, Department of Pathology, Herlev Hospital, University of 
      Copenhagen, Herlev Ringvej 75, 2730 Herlev, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20131205
PL  - Egypt
TA  - Int J Breast Cancer
JT  - International journal of breast cancer
JID - 101568103
PMC - PMC3870126
EDAT- 2014/01/03 06:00
MHDA- 2014/01/03 06:01
PMCR- 2013/12/05
CRDT- 2014/01/03 06:00
PHST- 2013/09/03 00:00 [received]
PHST- 2013/11/12 00:00 [revised]
PHST- 2013/11/12 00:00 [accepted]
PHST- 2014/01/03 06:00 [entrez]
PHST- 2014/01/03 06:00 [pubmed]
PHST- 2014/01/03 06:01 [medline]
PHST- 2013/12/05 00:00 [pmc-release]
AID - 10.1155/2013/368731 [doi]
PST - ppublish
SO  - Int J Breast Cancer. 2013;2013:368731. doi: 10.1155/2013/368731. Epub 2013 Dec 5.